|

Firmonertinib Mesilate Tablets Clinical Trials

1 actively recruiting trial

Pipeline

Phase 3: 1

Top Sponsors

  • Allist Pharmaceuticals, Inc.1

Indications

  • eGFR1
  • NSCLC (Advanced Non-small Cell Lung Cancer)1
  • Lung Cancer1
  • Cancer1

Other1 trial

Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.